SOBI (SOBI) Q3 2026 earnings summary

Executive summary

• Q3 revenue rose 16% at CER to SEK 9,124M; excluding seasonal RSV royalties, portfolio growth was 26%. Nine-month revenue increased 23% at CER to SEK 24,150M.

• Strategic portfolio revenue grew 25% at CER to SEK 6,298M; launches and international markets supported momentum.

Financial highlights

• Q3 revenue was SEK 9,124M versus SEK 7,776M, up 17% at actual exchange rates.

• Adjusted gross profit was SEK 7,195M, up 16%; adjusted gross margin was 79% versus 80%.

• Adjusted EBITA was SEK 4,087M, up 11%; margin was 45% versus 47%.

• Profit for the period was SEK 2,349M versus a loss of SEK 2,895M; diluted EPS was SEK 6.69 versus negative SEK 8.32.

• Operating cash flow was SEK 1,871M, up 2%.

Outlook and guidance

• FY26 revenue growth guidance rose to high-teens to low-20s% at CER from mid- to high-teens; adjusted EBITA margin guidance remains mid- to high-30s%.

• Tryngolza’s European launch is expected earlier in 2027 than planned, following a positive CHMP opinion; an EU decision was expected in Q4 2026.

• Launch preparation and the Gamifant sepsis trial remain investment priorities; some NASP launch costs shifted to 2027, balanced by cost controls and resource reallocation.